{
    "pmcid": "11148044",
    "qa_pairs": {
        "How do the nanobodies derived from LamaMice benefit from the camelid VHH framework sequences?": [
            "They reduce risks associated with aggregation and improve stability and solubility.",
            "They increase the affinity for the SARS-CoV-2 spike protein.",
            "They enhance the immune response to bacterial infections.",
            "They allow for the production of light chain antibodies."
        ],
        "What is a potential limitation of the LamaMouse model mentioned in the study?": [
            "A smaller B cell repertoire compared to camelids.",
            "Inability to produce antibodies against viral antigens.",
            "Higher risk of antibody aggregation.",
            "Lack of cross-reactivity with SARS-CoV-2 variants."
        ],
        "What is the primary advantage of using the LamaMouse model for nanobody production compared to traditional camelid methods?": [
            "The ease of mouse breeding and genetic manipulation.",
            "The ability to produce light chain antibodies.",
            "The use of a viral vector for immunization.",
            "The incorporation of human IgH locus into mice."
        ],
        "What method was used to clone the VHH-repertoire from splenocyte cDNA in the study?": [
            "Cloning into a mammalian expression vector.",
            "Cloning into a bacterial expression vector.",
            "Cloning into a yeast expression vector.",
            "Cloning into a viral expression vector."
        ],
        "Which specific nanobody demonstrated the ability to neutralize both the Wuhan strain and the Omicron BA.2 variant of SARS-CoV-2?": [
            "VHH 6SG-G12",
            "VHH 5AB-F9",
            "VHH 3CD-E7",
            "VHH 8JK-H4"
        ]
    }
}